Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

337.92 -4.48 (-1.31%)

Streaming Delayed Price Updated: 1:40 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

61 62 Next >

Weight-Loss Drugs Spooked Medical Device Stocks. Did Investors Overreact? ↗

October 27, 2023

Makers of devices to treat obesity-related conditions have struggled recently. Analysts say there's more to the story.

Via Investor's Business Daily

3 Pharma Stocks That Are Screaming Buys in October ↗

October 26, 2023

Each company delivers an above-average dividend and revenue growth.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 25, 2023

Via Benzinga

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Looking At Amgen's Recent Unusual Options Activity ↗

October 23, 2023

Via Benzinga

Amgen Unusual Options Activity For October 17 ↗

October 17, 2023

Via Benzinga

Amgen Layoffs 2023: What to Know About the Latest AMGN Job Cuts ↗

October 24, 2023

Investors appear to be viewing Amgen's recent job cuts as a positive today, with buying pressure resulting in a 1% move higher in AMGN stock.

Via InvestorPlace

Topics Workforce

Why These 3 Equal-Weighted ETFs Deserve a Portfolio Spot

October 19, 2023

These three equally-weighted exchange traded funds that offer superior diversification and risk adjusted returns are worth a look.

Via MarketBeat

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today ↗

October 16, 2023

Via Benzinga

Johnson & Johnson Stock: Is Now the Time to Sell? ↗

October 14, 2023

Conservative investors buy Johnson & Johnson for the dividend, but that payout is less safe after its Kenvue spinoff

Via InvestorPlace

In-Depth Analysis: Amgen Versus Competitors In Biotechnology Industry ↗

October 13, 2023

Via Benzinga

Is This Dividend Stock a Screaming Buy After Its Latest Acquisition? ↗

October 13, 2023

The biotech is ending the year with a bang.

Via The Motley Fool

Is Amgen Stock a Buy Now? ↗

October 13, 2023

The company recently closed its acquisition of Horizon Therapeutics.

Via The Motley Fool

Check Out What Whales Are Doing With AMGN ↗

October 12, 2023

Via Benzinga

Prescriptions for Portfolio Health: 3 Resilient Healthcare Stocks

October 12, 2023

During the peak of the recent selloff, the healthcare sector outshone, with three stocks showing resilience and impressive upward moves.

Via MarketBeat

Topics ETFs

Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade ↗

October 11, 2023

The company has growing pipeline optionality, according to the upgrade report.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 11, 2023

Via Benzinga

Expert Ratings for Amgen ↗

October 11, 2023

Via Benzinga

Should You Still Buy the Nasdaq's Best-Performing September Stocks? ↗

October 10, 2023

Tech stocks sold off last month, but these three were gainers.

Via The Motley Fool

$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today ↗

October 09, 2023

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 09, 2023

Via Benzinga

2 Magnificent Dividend Stocks to Buy Hand Over Fist in October ↗

October 09, 2023

These two healthcare stocks are reliable passive income vehicles.

Via The Motley Fool

Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid ↗

October 09, 2023

Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion.

Via Investor's Business Daily

Amgen's Adcomm Meeting Paves Way To Launch Boost For Mirati Therapeutics' Lung Cancer Drug: Analysts ↗

October 06, 2023

According to a report on Thursday, French pharma company Sanofi SA (NASDAQ: SNY) is reportedly exploring a potential acquisition of cancer drugmaker Mirati Therapeutics Inc (NASDAQ: MRTX).

Via Benzinga

FDA Adcomm Gives Thumbs Down To Amgen's Lumakras For Advanced Form Of Lung Cancer ↗

October 06, 2023

FDA advisers concluded that the data from a late-stage trial lacked the requisite reliability to endorse the traditional approval of Amgen Inc's (NASDAQ: AMGN) Lumakras for patients afflicted with an...

Via Benzinga

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

Should You Still Buy the Dow Jones' Best-Performing September Stocks? ↗

October 04, 2023

A handful of blue-chip tickers defied the bigger bearish tide last month, but that doesn't necessarily make these stocks a buy.

Via The Motley Fool

Topics Stocks

Is Amgen's Lung Cancer Drug Lumakras Up to the Mark? FDA Briefing Raises Concerns ↗

October 03, 2023

The FDA released briefing documents ahead of Oncologic Drugs Advisory Committee meeting scheduled for October 5 to review Amgen Inc's (NASDAQ:

Via Benzinga

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗

October 03, 2023

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration

Via Benzinga

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.